Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway.

Genthe JR, Min J, Farmer DM, Shelat AA, Grenet JA, Lin W, Finkelstein D, Vrijens K, Chen T, Guy RK, Clements WK, Roussel MF.

ACS Chem Biol. 2019 Jul 19;14(7):1673. doi: 10.1021/acschembio.9b00488. Epub 2019 Jun 28. No abstract available.

PMID:
31251562
2.

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.

Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, Patel NB, Nakrani VB, Shaikh FA, Patel HV; on behalf of the ZYAN1 Trial Investigators.

Am J Nephrol. 2019;49(6):470-478. doi: 10.1159/000500232. Epub 2019 May 21.

PMID:
31112954
3.

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.

Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, Jeon JY, Fu Q, Buelow DR, Pioso M, Hu S, Inaba H, Ribeiro RC, Rubnitz JE, Gruber TA, Guy RK, Baker SD.

Nat Commun. 2019 May 16;10(1):2189. doi: 10.1038/s41467-019-09917-0.

4.

Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents.

Ling T, Maier J, Das S, Budhraja A, Bassett R, Potts MB, Shelat A, Rankovic Z, Opferman JT, Rivas F.

Eur J Med Chem. 2019 Feb 15;164:391-398. doi: 10.1016/j.ejmech.2018.12.059. Epub 2018 Dec 24.

5.

Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.

Loh AHP, Stewart E, Bradley CL, Chen X, Daryani V, Stewart CF, Calabrese C, Funk A, Miller G, Karlstrom A, Krafcik F, Goshorn DR, Vogel P, Bahrami A, Shelat A, Dyer MA.

Cancer Lett. 2019 Feb 1;442:262-270. doi: 10.1016/j.canlet.2018.10.033. Epub 2018 Nov 3.

PMID:
30395907
6.

Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses.

Stewart E, McEvoy J, Wang H, Chen X, Honnell V, Ocarz M, Gordon B, Dapper J, Blankenship K, Yang Y, Li Y, Shaw TI, Cho JH, Wang X, Xu B, Gupta P, Fan Y, Liu Y, Rusch M, Griffiths L, Jeon J, Freeman BB 3rd, Clay MR, Pappo A, Easton J, Shurtleff S, Shelat A, Zhou X, Boggs K, Mulder H, Yergeau D, Bahrami A, Mardis ER, Wilson RK, Zhang J, Peng J, Downing JR, Dyer MA; St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project.

Cancer Cell. 2018 Sep 10;34(3):411-426.e19. doi: 10.1016/j.ccell.2018.07.012. Epub 2018 Aug 23.

7.

Erratum: BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action.

Twarog NR, Stewart E, Hammill CV, Shelat AA.

Sci Rep. 2018 May 17;8:46970. doi: 10.1038/srep46970.

8.

The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.

Bharatham N, Slavish PJ, Shadrick WR, Young BM, Shelat AA.

J Mol Graph Model. 2018 May;81:197-210. doi: 10.1016/j.jmgm.2018.03.005. Epub 2018 Mar 22.

9.

Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria.

Riniker S, Landrum GA, Montanari F, Villalba SD, Maier J, Jansen JM, Walters WP, Shelat AA.

Version 2. F1000Res. 2017 Jul 17 [revised 2018 Jan 1];6:1136. doi: 10.12688/f1000research.11905.2. eCollection 2017.

10.

Novel vitexin-inspired scaffold against leukemia.

Ling T, Lang W, Feng X, Das S, Maier J, Jeffries C, Shelat A, Rivas F.

Eur J Med Chem. 2018 Feb 25;146:501-510. doi: 10.1016/j.ejmech.2018.01.004. Epub 2018 Jan 31.

PMID:
29407975
11.

Establishing a Preclinical Multidisciplinary Board for Brain Tumors.

Nimmervoll BV, Boulos N, Bianski B, Dapper J, DeCuypere M, Shelat A, Terranova S, Terhune HE, Gajjar A, Patel YT, Freeman BB, Onar-Thomas A, Stewart CF, Roussel MF, Guy RK, Merchant TE, Calabrese C, Wright KD, Gilbertson RJ.

Clin Cancer Res. 2018 Apr 1;24(7):1654-1666. doi: 10.1158/1078-0432.CCR-17-2168. Epub 2018 Jan 4.

12.

Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening.

Ortiz D, Guiguemde WA, Hammill JT, Carrillo AK, Chen Y, Connelly M, Stalheim K, Elya C, Johnson A, Min J, Shelat A, Smithson DC, Yang L, Zhu F, Guy RK, Landfear SM.

PLoS Negl Trop Dis. 2017 Dec 29;11(12):e0006157. doi: 10.1371/journal.pntd.0006157. eCollection 2017 Dec.

13.

Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.

Shadrick WR, Slavish PJ, Chai SC, Waddell B, Connelly M, Low JA, Tallant C, Young BM, Bharatham N, Knapp S, Boyd VA, Morfouace M, Roussel MF, Chen T, Lee RE, Kiplin Guy R, Shelat AA, Potter PM.

Bioorg Med Chem. 2018 Jan 1;26(1):25-36. doi: 10.1016/j.bmc.2017.10.042. Epub 2017 Nov 4.

14.

Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4.

Diouf B, Lin W, Goktug A, Grace CRR, Waddell MB, Bao J, Shao Y, Heath RJ, Zheng JJ, Shelat AA, Relling MV, Chen T, Evans WE.

SLAS Discov. 2018 Feb;23(2):164-173. doi: 10.1177/2472555217735035. Epub 2017 Oct 6.

15.

Orthotopic patient-derived xenografts of paediatric solid tumours.

Stewart E, Federico SM, Chen X, Shelat AA, Bradley C, Gordon B, Karlstrom A, Twarog NR, Clay MR, Bahrami A, Freeman BB 3rd, Xu B, Zhou X, Wu J, Honnell V, Ocarz M, Blankenship K, Dapper J, Mardis ER, Wilson RK, Downing J, Zhang J, Easton J, Pappo A, Dyer MA.

Nature. 2017 Sep 7;549(7670):96-100. doi: 10.1038/nature23647. Epub 2017 Aug 30.

16.

Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway.

Genthe JR, Min J, Farmer DM, Shelat AA, Grenet JA, Lin W, Finkelstein D, Vrijens K, Chen T, Guy RK, Clements WK, Roussel MF.

ACS Chem Biol. 2017 Sep 15;12(9):2436-2447. doi: 10.1021/acschembio.7b00527. Epub 2017 Aug 29. Erratum in: ACS Chem Biol. 2019 Jul 19;14(7):1673.

17.

Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox.

Yang J, Milasta S, Hu D, AlTahan AM, Interiano RB, Zhou J, Davidson J, Low J, Lin W, Bao J, Goh P, Nathwani AC, Wang R, Wang Y, Ong SS, Boyd VA, Young B, Das S, Shelat A, Wu Y, Li Z, Zheng JJ, Mishra A, Cheng Y, Qu C, Peng J, Green DR, White S, Guy RK, Chen T, Davidoff AM.

Cancer Res. 2017 Sep 1;77(17):4626-4638. doi: 10.1158/0008-5472.CAN-16-0826. Epub 2017 Jul 6.

18.

Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase.

Scott DC, Hammill JT, Min J, Rhee DY, Connelly M, Sviderskiy VO, Bhasin D, Chen Y, Ong SS, Chai SC, Goktug AN, Huang G, Monda JK, Low J, Kim HS, Paulo JA, Cannon JR, Shelat AA, Chen T, Kelsall IR, Alpi AF, Pagala V, Wang X, Peng J, Singh B, Harper JW, Schulman BA, Guy RK.

Nat Chem Biol. 2017 Aug;13(8):850-857. doi: 10.1038/nchembio.2386. Epub 2017 Jun 5.

19.

Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention.

Smallwood HS, Duan S, Morfouace M, Rezinciuc S, Shulkin BL, Shelat A, Zink EE, Milasta S, Bajracharya R, Oluwaseum AJ, Roussel MF, Green DR, Pasa-Tolic L, Thomas PG.

Cell Rep. 2017 May 23;19(8):1640-1653. doi: 10.1016/j.celrep.2017.04.039.

20.

Shared Consensus Machine Learning Models for Predicting Blood Stage Malaria Inhibition.

Verras A, Waller CL, Gedeck P, Green DV, Kogej T, Raichurkar A, Panda M, Shelat AA, Clark J, Guy RK, Papadatos G, Burrows J.

J Chem Inf Model. 2017 Mar 27;57(3):445-453. doi: 10.1021/acs.jcim.6b00572. Epub 2017 Mar 17.

PMID:
28257198
21.

Diversity-oriented natural product platform identifies plant constituents targeting Plasmodium falciparum.

Zhang J, Bowling JJ, Smithson D, Clark J, Jacob MR, Khan SI, Tekwani BL, Connelly M, Samoylenko V, Ibrahim MA, Zaki MA, Wang M, Hester JP, Tu Y, Jeffries C, Twarog N, Shelat AA, Walker LA, Muhammad I, Guy RK.

Malar J. 2016 May 10;15(1):270. doi: 10.1186/s12936-016-1313-7.

22.

BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action.

Twarog NR, Stewart E, Hammill CV, Shelat AA.

Sci Rep. 2016 May 10;6:25523. doi: 10.1038/srep25523. Erratum in: Sci Rep. 2018 May 17;8:46970.

23.

Evaluation of artemisinins for the treatment of acute myeloid leukemia.

Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1231-43. doi: 10.1007/s00280-016-3038-2. Epub 2016 Apr 28.

24.

Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis.

Twarog NR, Low JA, Currier DG, Miller G, Chen T, Shelat AA.

PLoS One. 2016 Feb 17;11(2):e0149439. doi: 10.1371/journal.pone.0149439. eCollection 2016.

25.

Synthesis and evaluation of colletoic acid core derivatives.

Ling T, Gautam LN, Griffith E, Das S, Lang W, Shadrick WR, Shelat A, Lee R, Rivas F.

Eur J Med Chem. 2016 Mar 3;110:126-32. doi: 10.1016/j.ejmech.2016.01.027. Epub 2016 Jan 20.

PMID:
26820555
26.

The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.

Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O.

Oncotarget. 2016 Feb 23;7(8):8613-24. doi: 10.18632/oncotarget.6937. Review.

27.

Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.

Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF.

J Neurooncol. 2016 Jan;126(2):225-34. doi: 10.1007/s11060-015-1965-0. Epub 2015 Oct 30.

28.

Discovery of Small Molecules that Inhibit the Disordered Protein, p27(Kip1).

Iconaru LI, Ban D, Bharatham K, Ramanathan A, Zhang W, Shelat AA, Zuo J, Kriwacki RW.

Sci Rep. 2015 Oct 28;5:15686. doi: 10.1038/srep15686.

29.

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.

Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF.

Cancer Res. 2015 Sep 15;75(18):3879-89. doi: 10.1158/0008-5472.CAN-15-0030. Epub 2015 Jul 21.

30.

Nuclear ULK1 promotes cell death in response to oxidative stress through PARP1.

Joshi A, Iyengar R, Joo JH, Li-Harms XJ, Wright C, Marino R, Winborn BJ, Phillips A, Temirov J, Sciarretta S, Kriwacki R, Peng J, Shelat A, Kundu M.

Cell Death Differ. 2016 Feb;23(2):216-30. doi: 10.1038/cdd.2015.88. Epub 2015 Jul 3.

31.

The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities.

Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, Dyer MA.

Dev Biol. 2016 Mar 15;411(2):287-293. doi: 10.1016/j.ydbio.2015.03.001. Epub 2015 Jun 9.

32.

Development and characterization of a human orthotopic neuroblastoma xenograft.

Stewart E, Shelat A, Bradley C, Chen X, Federico S, Thiagarajan S, Shirinifard A, Bahrami A, Pappo A, Qu C, Finkelstein D, Sablauer A, Dyer MA.

Dev Biol. 2015 Nov 15;407(2):344-55. doi: 10.1016/j.ydbio.2015.02.002. Epub 2015 Apr 9.

33.

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.

Gupte A, Baker EK, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk AM, Taylor S, Lackovic K, Karlström Å, Mutsaers AJ, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer MA, Simpson KJ, Walkley CR.

Clin Cancer Res. 2015 Jul 15;21(14):3216-29. doi: 10.1158/1078-0432.CCR-14-3026. Epub 2015 Apr 10.

34.

A high-throughput screen reveals new small-molecule activators and inhibitors of pantothenate kinases.

Sharma LK, Leonardi R, Lin W, Boyd VA, Goktug A, Shelat AA, Chen T, Jackowski S, Rock CO.

J Med Chem. 2015 Feb 12;58(3):1563-8. doi: 10.1021/jm501585q. Epub 2015 Jan 21.

35.

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.

Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gómez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martínez MS, Miller G, Rodríguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1. Erratum in: Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764.

36.

Targeting the DNA repair pathway in Ewing sarcoma.

Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlström Å, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA.

Cell Rep. 2014 Nov 6;9(3):829-41. doi: 10.1016/j.celrep.2014.09.028. Epub 2014 Oct 23.

37.

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF.

Cancer Cell. 2014 Apr 14;25(4):516-29. doi: 10.1016/j.ccr.2014.02.009. Epub 2014 Mar 27.

38.

UPLC-MS-ELSD-PDA as a powerful dereplication tool to facilitate compound identification from small-molecule natural product libraries.

Yang J, Liang Q, Wang M, Jeffries C, Smithson D, Tu Y, Boulos N, Jacob MR, Shelat AA, Wu Y, Ravu RR, Gilbertson R, Avery MA, Khan IA, Walker LA, Guy RK, Li XC.

J Nat Prod. 2014 Apr 25;77(4):902-9. doi: 10.1021/np4009706. Epub 2014 Mar 11.

39.

Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors.

Guo K, Shelat AA, Guy RK, Kastan MB.

J Biomol Screen. 2014 Apr;19(4):538-46. doi: 10.1177/1087057113520325. Epub 2014 Jan 24. Erratum in: J Biomol Screen. 2014 Dec;19(10):1418.

PMID:
24464432
40.

Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study.

Bharatham N, Bharatham K, Shelat AA, Bashford D.

J Chem Inf Model. 2014 Feb 24;54(2):648-59. doi: 10.1021/ci4004656. Epub 2014 Jan 21.

41.

Targeting oxidative stress in embryonal rhabdomyosarcoma.

Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, Krafcik F, Lang WH, Wierdl M, Tsurkan L, Tolleman V, Federico SM, Morton C, Lu C, Ding L, Easton J, Rusch M, Nagahawatte P, Wang J, Parker M, Wei L, Hedlund E, Finkelstein D, Edmonson M, Shurtleff S, Boggs K, Mulder H, Yergeau D, Skapek S, Hawkins DS, Ramirez N, Potter PM, Sandoval JA, Davidoff AM, Mardis ER, Wilson RK, Zhang J, Downing JR, Dyer MA; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project.

Cancer Cell. 2013 Dec 9;24(6):710-24. doi: 10.1016/j.ccr.2013.11.002.

42.

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.

Gottardo NG, Hansford JR, McGlade JP, Alvaro F, Ashley DM, Bailey S, Baker DL, Bourdeaut F, Cho YJ, Clay M, Clifford SC, Cohn RJ, Cole CH, Dallas PB, Downie P, Doz F, Ellison DW, Endersby R, Fisher PG, Hassall T, Heath JA, Hii HL, Jones DT, Junckerstorff R, Kellie S, Kool M, Kotecha RS, Lichter P, Laughton SJ, Lee S, McCowage G, Northcott PA, Olson JM, Packer RJ, Pfister SM, Pietsch T, Pizer B, Pomeroy SL, Remke M, Robinson GW, Rutkowski S, Schoep T, Shelat AA, Stewart CF, Sullivan M, Taylor MD, Wainwright B, Walwyn T, Weiss WA, Williamson D, Gajjar A.

Acta Neuropathol. 2014 Feb;127(2):189-201. doi: 10.1007/s00401-013-1213-7. Epub 2013 Nov 22.

43.

Metabolic activation of CaMKII by coenzyme A.

McCoy F, Darbandi R, Lee HC, Bharatham K, Moldoveanu T, Grace CR, Dodd K, Lin W, Chen SI, Tangallapally RP, Kurokawa M, Lee RE, Shelat AA, Chen T, Green DR, Harris RA, Lin SH, Fissore RA, Colbran RJ, Nutt LK.

Mol Cell. 2013 Nov 7;52(3):325-39. doi: 10.1016/j.molcel.2013.08.043. Epub 2013 Oct 3. Erratum in: Mol Cell. 2013 Nov 7;52(3):468.

44.

A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia.

Singh H, Shelat AA, Singh A, Boulos N, Williams RT, Guy RK.

J Biomol Screen. 2014 Jan;19(1):158-67. doi: 10.1177/1087057113501081. Epub 2013 Aug 29.

45.

Cheminformatics aspects of high throughput screening: from robots to models: symposium summary.

Jane Tseng Y, Martin E, G Bologa C, Shelat AA.

J Comput Aided Mol Des. 2013 May;27(5):443-53. doi: 10.1007/s10822-013-9646-6. Epub 2013 May 1.

46.

Matching by propensity score in cohort studies with three treatment groups.

Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S.

Epidemiology. 2013 May;24(3):401-9. doi: 10.1097/EDE.0b013e318289dedf.

PMID:
23532053
47.

Identification of small molecule activators of BMP signaling.

Vrijens K, Lin W, Cui J, Farmer D, Low J, Pronier E, Zeng FY, Shelat AA, Guy K, Taylor MR, Chen T, Roussel MF.

PLoS One. 2013;8(3):e59045. doi: 10.1371/journal.pone.0059045. Epub 2013 Mar 19.

48.

One-to-many propensity score matching in cohort studies.

Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S.

Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:69-80. doi: 10.1002/pds.3263.

PMID:
22552982
49.

Global phenotypic screening for antimalarials.

Guiguemde WA, Shelat AA, Garcia-Bustos JF, Diagana TT, Gamo FJ, Guy RK.

Chem Biol. 2012 Jan 27;19(1):116-29. doi: 10.1016/j.chembiol.2012.01.004. Review.

50.

An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ.

Cancer Cell. 2011 Sep 13;20(3):384-99. doi: 10.1016/j.ccr.2011.08.013.

Supplemental Content

Loading ...
Support Center